Surface Oncology, Inc.
(NASDAQ : SURF)

( )
SURF PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.32%344.640.0%$4295.54m
BNTXBioNTech SE 1.78%297.590.0%$826.55m
NVAXNovavax, Inc. -0.73%134.0079.4%$753.23m
AMGNAmgen, Inc. -0.26%208.131.4%$524.80m
REGNRegeneron Pharmaceuticals, Inc. 0.00%592.152.7%$478.99m
SNSSSunesis Pharmaceuticals, Inc. 0.00%6.210.7%$434.10m
GILDGilead Sciences, Inc. -0.66%67.281.0%$395.23m
CCXIChemoCentryx, Inc. -0.09%33.692.9%$386.15m
ILMNIllumina, Inc. -0.02%417.093.3%$357.10m
XLRNAcceleron Pharma, Inc. 0.00%173.785.3%$335.39m
OCGNOcugen, Inc. 5.25%9.630.0%$319.26m
VRTXVertex Pharmaceuticals, Inc. -0.15%183.801.9%$273.65m
BIIBBiogen, Inc. 0.00%271.121.8%$271.81m
XENEXenon Pharmaceuticals, Inc. 0.00%30.570.4%$164.85m
CRSPCRISPR Therapeutics AG 1.57%96.550.6%$161.56m

Company Profile

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also include licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.